Early Management of CML

Naranie Shanmuganathan, Timothy P. Hughes

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Purpose of Review: The marked improvement in clinical outcomes for patients with chronic myeloid leukaemia (CML) can be solely attributed to the introduction of targeted therapies against the fusion oncoprotein, BCR-ABL1. However, patient responses, although generally positive, remain heterogenous. Careful drug selection, ensuring the optimal TKI, is chosen for each patient and involves a complex decision process which incorporates consideration of numerous factors. Recent Findings: For some patients, with disease characteristics that indicate adverse intrinsic disease biology, more potent BCR-ABL1 inhibition is often appropriate, whereas other patients with major co-morbidities will benefit from a less aggressive approach to avoid life-shortening toxicities. For the vast majority of patients, the long-term goal of therapy will be the achievement of a deep molecular response and subsequent treatment-free remission and this consideration will play a large part in the drug selection process. Summary: We explore early management of CML, from the first presentation through to frontline therapy selection.

Original languageEnglish
Pages (from-to)480-491
Number of pages12
JournalCurrent Hematologic Malignancy Reports
Volume14
Issue number6
DOIs
Publication statusPublished or Issued - Dec 2019

Keywords

  • Deep molecular responses
  • Drug toxicity
  • TKI
  • Treatment-free remission

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this